Human umbilical cord blood-derived mesenchymal stem cells improve functional recovery through thrombospondin1, pantraxin3, and vascular endothelial growth factor in the ischemic ra... von Park, Hyung Woo, Moon, Hyo-Eun, Kim, Hye-Soo R., Paek, Seung Leal, Kim, Yona, Chang, Jong Wook, Yang, Yoon Sun, Kim, KwanWoo, Oh, Wonil, Hwang, Jae Ha, Kim, Jin Wook, Kim, Dong Gyu, Paek, Sun Ha

Volltext

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO an... von Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D.S.W., Yang, J.C.-H., Azrif, M., Mitsudomi, T., Park, K., Soo, R.A., Chang, J.W.C., Alip, A., Peters, S., Douillard, J.-Y.

Volltext

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer von Planchard, D., Reinmuth, N., Orlov, S., Fischer, J.R., Sugawara, S., Mandziuk, S., Marquez-Medina, D., Novello, S., Takeda, Y., Soo, R., Park, K., McCleod, M., Geater, S.L., Powell, M., May, R., Scheuring, U., Stockman, P., Kowalski, D.

Volltext

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma von Kim, H.R., Lim, S.M., Kim, H.J., Hwang, S.K., Park, J.K., Shin, E., Bae, M.K., Ou, S.-H.I., Wang, J., Jewell, S.S., Kang, D.R., Soo, R.A., Haack, H., Kim, J.H., Shim, H.S., Cho, B.C.

Volltext

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Can... von Nokihara, H., Lu, S., Mok, T.S.K., Nakagawa, K., Yamamoto, N., Shi, Y.K., Zhang, L., Soo, R.A., Yang, J.C., Sugawara, S., Nishio, M., Takahashi, T., Goto, K., Chang, J., Maemondo, M., Ichinose, Y., Cheng, Y., Lim, W.T., Morita, S., Tamura, T.

Volltext

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies von Wong, A.L., Soo, R.A., Tan, D.S., Lee, S.C., Lim, J.S., Marban, P.C., Kong, L.R., Lee, Y.J., Wang, L.Z., Thuya, W.L., Soong, R., Yee, M.Q., Chin, T.M., Cordero, M.T., Asuncion, B.R., Pang, B., Pervaiz, S., Hirpara, J.L., Sinha, A., Xu, W.W., Yuasa, M., Tsunoda, T., Motoyama, M., Yamauchi, T., Goh, B.C.

Volltext

Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or withou... von Soong, R., Shah, N., Salto-Tellez, M., Tai, B. C., Soo, R. A., Han, H. C., Ng, S. S., Tan, W. L., Zeps, N., Joseph, D., Diasio, R. B., Iacopetta, B.

Volltext

ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment von Kowalski, D.M., Reinmuth, N., Orlov, S.V., Fischer, J.R., Sugawara, S., Mandziuk, S., Medine, D.M., Novello, S., Takeda, Y., Soo, R.A., Park, K., McCleod, M., Geater, S.L., Powell, M., May, R., Stockman, P., Planchard, D.

Volltext

IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carbo... von Socinski, M.A., Rittmeyer, A., Shapovalov, D., Orlandi, F., McCleod, M., Soo, R.A., Palmero, R., Kozuki, T., Migliorino, M.R., Koynov, K.D., Berard, H., Hughes, B.G.M., Yu, W., Graupner, V., Sun, S.W., Kowanetz, M., Hoang, T., Lin, W., Jotte, R.M.

Volltext

MS01.03 Overcoming Resistance — Clinical Results? von Soo, R.

Volltext

Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag) von Hochmair, M.J., Morabito, A., Hao, D., Yang, C.-T., Soo, R.A., Yang, J.C.-H., Gucalp, R., Halmos, B., Wang, L., Golembesky, A., Märten, A., Cufer, T.

Volltext

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies von Yong, W.P., Goh, B.C., Soo, R.A., Toh, H.C., Ethirajulu, K., Wood, J., Novotny-Diermayr, V., Lee, S.C., Yeo, W.L., Chan, D., Lim, D., Seah, E., Lim, R., Zhu, J.

Volltext

Near-future ocean acidification causes differences in microbial associations within diverse coral reef taxa von Webster, N. S., Negri, A. P., Flores, F., Humphrey, C., Soo, R., Botté, E. S., Vogel, N., Uthicke, S.

Volltext

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report von Hardenberg, M.C., Patel, B., Matthews, C., Califano, R., Garcia Campelo, R., Grohe, C., Hong, M.H., Liu, G., Lu, S., de Marinis, F., Pérol, M., Soo, R.A., Stiles, B.M., Tiseo, M., Tsuboi, M.

Volltext

Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations von Solomon, B.J., Martini, J.-F., Ou, S.-H.I., Chiari, R., Soo, R.A., Bearz, A., Li, S., Thurm, H., Lin, C.-C., Riely, G.J., Bauer, T.M., Shaw, A.T.

Volltext

MS28.04 Combination with Targeted Therapies von Soo, R.

Volltext

Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation von Viteri, S., Chang, G.-C., Chiari, R., Cho, B.C., Ciardiello, F., Curigliano, G., Hida, T., Lee, D.H., Lim, W.T.D., Lin, C.-C., Martinez, A., Murakami, H., Natsume, I., Nishio, M., Paz-Ares, L., Soo, R.A., Cattan, V., Gandossi, E., Heck, H., Park, K.

Volltext

Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC) von Peters, S., Shaw, A.T., Besse, B., Felip, E., Solomon, B.J., Soo, R.A., Bearz, A., Gadgee, S.M., Lin, C.-C., Kao, S., Seto, T., Masters, E.T., Abbattista, A., Clancy, J.S., Thurm, H., Reisman, A., Camidge, D.R.

Volltext

Phase Ib study of safety and tolerability of selinexor in Asian patients with advanced solid cancers von Heong, V Y M, Goh, M L, Yong, W P, Soo, R A, Chee, C E, Raghav, S, Goh, B-C, Lee, S C, Lim, J, Wong, A, Tan, D S P

Volltext

EGFR mutation status plays a critical role in determining CD151 expression in non-small cell lung cancer von Wong, A.H.P., Nga, M.E., Tam, J.K.C., Soo, R., Tran, T.

Volltext